Can you explain policy as it relates to biosimilars, including considerations that apply to

Can you explain policy as it relates to biosimilars, including considerations that apply to "extrapolation," "substitutability," and/or "interchangeability" for anti-TNF biosimilars?

Can you explain current policy guidance as it relates to biosimilars, including considerations that do or do not apply to “extrapolation,” “substitutability,” and/or “interchangeability” for anti-TNF biosimilars? And what are the product naming guidelines?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College